Cell Culture Dish, Inc.

Our latest guest article, highlights the value of peptones as media additives in biopharmaceutical applications, offering improved consistency and control compared to complex additives like fetal bovine serum (FBS). Derived from yeasts, plants, or animals, they are a mixture of polypeptides, amino acids, trace metals, and nutrients. Peptones enhance cell growth, viability, and productivity while reducing variability and risks associated with FBS. https://lnkd.in/g6BNPVz3

In this podcast, we spoke with Dr. George Wang, Vice President of Discovery and Preclinical Services at WuXi Biologics about the importance of identifying potential manufacturing, stability, and scalability challenges early to mitigate risks, reduce costs, and streamline drug development timelines. By evaluating factors such as solubility, stability, and manufacturability during initial candidate screening, companies can avoid costly setbacks later in the process. Advanced tools like high-throughput assays, computational modeling, and AI-based predictions are now essential for these evaluations. https://lnkd.in/gBRX-nsA

In our latest podcast with Jeremy Guo, SVP, Head of Drug Product Development & Clinical DP Network, WuXi Biologics we discussed both the challenges and innovations associated with developing high-concentration protein formulations. High-concentration formulations, which typically exceed 100 mg/mL, are essential for subcutaneous or intramuscular administration, shorter treatment times, and patient convenience, especially for chronic diseases like rheumatoid arthritis and various cancers. However, increasing the protein concentration introduces challenges such as increased viscosity and protein aggregation, which in turn impacts the manufacturability, stability, and delivery of drug products (DPs). Dr. Guo explains that these challenges are particularly pronounced when scaling up production and during the drug delivery process, where issues such as filtration and sterility assurance come into play. https://lnkd.in/gzyrerct

Join WuXi Biologics and Cell Culture Dish, Inc. for an insightful webinar with about how viral clearance critically impacts continuous manufacturing, with an emphasis on meeting key regulatory guidelines. Continuous manufacturing runs nonstop, making the removal or inactivation of viral contaminants in biologic products particularly challenging. Yuanyuan Chen, Senior Director discusses the complexities involved in designing viral clearance studies for continuous processes, focusing on technical hurdles like scale-down models, virus spiking strategies, and sample representativeness. Attendees gain practical insights into innovative solutions supported by real-world case studies. https://lnkd.in/g8zUvbYE

In our latest podcast, we spoke with Isha Dey, Senior Scientist, Cell Biology R&D, at Thermo Fisher Scientific about the challenges researchers face in selecting appropriate cell culture conditions due to variability in cell lines, lack of standardized protocols, and inconsistent reagent quality. Thermo Fisher Scientific’s new Cell Culture Select Tool was developed to address these challenges by providing specific recommendations for media, FBS, and cultureware for over 150 cell lines, backed by extensive R&D data. https://lnkd.in/gejuYZWT

In our recent podcast, we spoke with Fran Gregory, PharmD, MBA, Vice President of Emerging Therapies at Cardinal Health about the cell and gene therapy landscape, innovative solutions to reduce cost, the regulatory environment, and reimbursement. https://lnkd.in/gTVKJQpe

In our latest podcast, we spoke with Ryan Bernhardt, CEO of Biosero and Jesse Mulcahy, Director and Head of Automation at Cellino about the importance of utilizing automation in cell therapy research and production and the potential of these technologies to transform the healthcare landscape and improve patient access. Don't miss this great conversation! https://lnkd.in/gwqzayGz

https://lnkd.in/gnQczVt2

https://lnkd.in/gWJwdCwS

https://lnkd.in/gc3H44uP